Electra Therapeutics (ETRA) investor relations material

Company overview and business model

• Focuses on precision medicines for immune-mediated diseases and cancer, leveraging SIRP-targeted monoclonal antibodies to selectively deplete disease-driving cells while sparing normal immune function.

• Lead candidate, ipsoprubart, is in global registrational trials for secondary hemophagocytic lymphohistiocytosis (sHLH); ELA822 targets chronic T cell-mediated diseases.

• Proprietary antibody library enables expansion into multiple indications without additional de novo discovery.

Financial performance and metrics

• Reported net losses of $62.0M in 2025 and $48.9M for the first half of 2026; accumulated deficit of $221.9M as of June 30, 2026.

• Operating expenses increased significantly due to R&D and headcount growth; cash, cash equivalents, and marketable securities totaled $97.7M as of June 30, 2026.

• No revenue generated to date; operations funded primarily through $301.4M in preferred stock and convertible note financings.

• Auditors included a going concern warning due to insufficient capital for 12 months of operations post-June 2026.

Use of proceeds and capital allocation

• Net proceeds will fund: (i) ipsoprubart development in sHLH through Phase 2/3 trial and BLA submission, (ii) ipsoprubart in T/NK cell malignancies, (iii) ELA822 clinical trials, and (iv) other R&D, working capital, and general corporate purposes.

• Proceeds may also be used for strategic investments, though no agreements are in place.

• Existing cash plus IPO proceeds expected to fund operations into the future, but not through full clinical development and commercialization.